Island Pharma one step closer to ISLA-101 dosing

–News Direct–

Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has officially commenced screening subjects for the ISLA-101 single ascending dose study. The company plans to repurpose ISLA-101, a well-established drug, for the prevention and treatment of dengue and other mosquito-borne diseases, addressing a significant global health concern. Three cohorts of healthy subjects will receive escalating doses of the drug to determine if these doses can safely achieve the required blood concentrations to combat the dengue virus. Dengue fever, a viral infection transmitted by infected mosquitoes, has seen a staggering increase in reported cases worldwide.

Foster said: Following on from ethics approval and also our recent Site Initiation Visit, we are delighted to now be one step closer to dosing subjects in this study."

The World Health Organisation said last month that Dengue fever will become a major threat in the southern US, southern Europe and new parts of Africa this decade. About half of the world's population is now at risk of dengue with an estimated 100400 million infections occurring each year.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Island Pharmaceuticals Ltd

comtex tracking


Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Nook Explorer journalist was involved in the writing and production of this article.